IP Library › Granted Patent US 11,667,742
Granted Patent B2
US 11,667,742 · App. 16/865,055 · Granted Jun 6, 2023

Compositions with high refractive index and Abbe number

Inventors: Azaam Alli (Jacksonville, FL); Bart A. Johnson (Laguna Beach, CA); Scott L. Joslin (Ponte Vedra Beach, FL); Ghulam Maharvi (Jacksonville, FL)
Assignee: Johnson & Johnson Surgical Vision, Inc.
C08F220/40G02B1/041
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,667,742
App. No.
16/865,055
Granted
Jun 6, 2023
Kind
B2
Abstract

Disclosed are co-polymers which are produced from reactive monomer mixtures and which have both high refractive index and a high Abbe number. These materials are well suited for use as implantable ophthalmic devices and have a refractive index which may be edited through application of energy. When used for an intraocular lens, the high refractive index allows for a thin lens which compresses to allow a small incision size.

Claims (38)

1. An ophthalmic device comprising a composition made by free radical polymerization of a reactive monomer mixture, the reactive monomer mixture comprising:

(a) at least one hydrophobic monomer;

(b) at least one monomer selected from hydrophilic monomers and hydroxyalkyl (meth)acrylate monomers, and any combination thereof; and

(c) a tricyclo[5.2.1.0 2,6 ]decanedimethanol di(meth)acrylate cross-linking agent;

wherein the composition exhibits a refractive index of at least 1.45 and an Abbe number of at least 39; and

wherein the ophthalmic device comprises an intraocular lens, contact lens, corneal inlay, corneal outlay, or corneal insert.

2. The ophthalmic device of claim 1 , wherein the hydrophobic monomer is a hydrophobic (meth)acrylate monomer selected from an aliphatic (meth)acrylate, an aromatic (meth)acrylate, a cycloaliphatic (meth)acrylate, and any combination thereof.

3. The ophthalmic device of claim 2 , wherein the hydrophobic (meth)acrylate is a cycloaliphatic (meth)acrylate selected from cyclohexyl acrylate, cyclohexylmethyl acrylate, cyclohexylmethyl methacrylate, 2-cyclohexylethyl acrylate, 2-cyclohexylethyl methacrylate, ethylene glycol dicyclopentenyl ether acrylate, and any combination thereof.

4. The ophthalmic device of claim 2 , wherein the hydrophobic (meth)acrylate is an aliphatic (meth)acrylate selected from C 1 -C 18 alkyl (meth)acrylates.

5. The ophthalmic device of claim 2 , wherein the hydrophobic (meth)acrylate is an aromatic (meth)acrylate selected from the group consisting of 2-phenylethyl (meth)acrylate, 2-phenoxyethyl (meth)acrylate, 4-chlorophenoxyethyl (meth)acrylate, 3-phenylpropyl (meth)acrylate, 4-phenylbutyl (meth)acrylate, 3-phenoxypropyl (meth)acrylate, 1,3-bis-phenylthiol-2-propyl (meth)acrylate, poly(ethylene glycol) phenyl ether (meth)acrylate, and any combination thereof.

6. The ophthalmic device of claim 1 , wherein the reactive monomer mixture comprises at least one hydrophilic monomer that is a poly(ethylene glycol)-containing monomer selected from poly(ethylene glycol) methacrylate and poly(ethylene glycol) methyl ether methacrylate.

7. The ophthalmic device of claim 1 , wherein the reactive monomer mixture comprises at least one hydroxyalkyl (meth)acrylate monomer selected from 2-hydroxyethyl (meth)acrylate, 2-hydroxypropyl (meth)acrylate, 3-hydroxypropyl (meth)acrylate, 2,3-dihydroxypropyl (meth)acrylate, dimethylhydroxyethyl (meth)acrylate, 4-hydroxybutyl (meth)acrylate, and any combination thereof.

8. The ophthalmic device of claim 1 , wherein the reactive monomer mixture comprises a mixture of a hydrophilic monomer and a hydroxyalkyl (meth)acrylate monomer, wherein the hydrophilic monomer is selected from poly(ethylene glycol) methacrylate and poly(ethylene glycol) methyl ether methacrylate, and wherein the hydroxyalkyl (meth)acrylate monomer is 2-hydroxyethyl acrylate.

9. The ophthalmic device of claim 1 , wherein the tricyclo[5.2.1.0 2,6 ]decanedimethanol di(meth)acrylate cross-linking agent is tricyclo[5.2.1.0 2,6 ]decanedimethanol diacrylate.

10. The ophthalmic device of claim 1 , further comprising at least one UV/HEV absorbing compound in the reactive monomer mixture, wherein the UV/HEV absorbing compound is selected from 2-(2′-hydroxy-5-methacrylyloxyethylphenyl)-2H-benzotriazole, 2-(2-cyano-2-(9H-thioxanthen-9-ylidene)acetamido)ethyl methacrylate, 2-(2-cyano-2-(9H-xanthen-9-ylidene)acetamido)ethyl methacrylate, 2-(2-cyano-2-(10-methylacridin-9(10H)-ylidene)acetamido)ethyl methacrylate, 3-(3-(tert-butyl)-5-(5-chloro-2H-benzo[d][1,2,3]triazol-2-yl)-4-hydroxyphenyl)propyl methacrylate, a compound of formula II:

wherein:

m and n are independently 0, 1, 2, 3, or 4;

T is a bond, O, or NR;

X is O, S, NR, SO, or SO 2 ;

Y is a linking group;

P g is a polymerizable group;

R at each occurrence is independently H, C 1 -C 6 alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, or Y—P g ;

R 1 and R 2 , when present, are independently at each occurrence C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 thioalkyl, C 3 -C 7 cycloalkyl, aryl, halo, hydroxy, amino, NR 3 R 4 , or benzyl,

wherein R 3 and R 4 are independently H or C 1 -C 6 alkyl, or two adjacent R 1 or R 2 groups, together with the carbon atoms to which they are attached, combine to form a cycloalkyl or aryl ring; and

EWG is an electron withdrawing group;

and any combination thereof.

11. The ophthalmic device of claim 1 , further comprising at least one diluent in the reactive monomer mixture.

12. The ophthalmic device of claim 1 , having a water content of between about 0 weight percent and about 15 weight percent.

13. The ophthalmic device of claim 1 , wherein the composition has a refractive index of at least 1.45 and an Abbe number of at least 45.

14. The ophthalmic device of claim 1 , wherein the free radical polymerization is a photopolymerization using a bisacylphosphine oxide initiator.

15. A method for making the ophthalmic device of claim 1 , the method comprising:

(a) providing a composition made by free radical polymerization of a reactive monomer mixture of claim 1 ; and

(b) forming an ophthalmic device.

16. The ophthalmic device of claim 3 , wherein the cycloaliphatic (meth)acrylate is ethylene glycol dicyclopentenyl ether acrylate.

17. The ophthalmic device of claim 7 , wherein the hydroxyalkyl (meth)acrylate monomer is 4-hydroxybutyl acrylate.

18. The ophthalmic device of claim 4 , wherein the aliphatic (meth)acrylate comprises a C 4 -C 8 linear alkyl group.

19. The ophthalmic device of claim 3 , wherein the reactive monomer mixture comprises the at least one cycloaliphatic (meth)acrylate in an amount between 50 and 80 weight percent.

20. The ophthalmic device of claim 1 , wherein the reactive monomer mixture comprises the tricyclo[5.2.1.0 2,6 ]decanedimethanol di(meth)acrylate cross-linking agent in an amount between 1 and 20 weight percent.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 1, 2020
From: ALLI, AZAAM; JOHNSON, BART A.; JOSLIN, SCOTT L.; MAHARVI, GHULAM
To: JOHNSON & JOHNSON SURGICAL VISION, INC.
Reel/Frame 052555/0657 →
Continuity (2)
Provisional Application 62843054 · May 3, 2019
Related Publication 20200347167A1 · Nov 5, 2020
Cited By (1)
US 12,460,032